Therapeutic Uses of Modified Relaxin Polypeptides
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 13/212,101, filed Aug 17, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,452,222 | Nucleic Acids Encoding Modified Relaxin Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 10,253,083 | Therapeutic Uses of Modified Relaxin Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 10,702,588 | Modified Relaxin Polypeptides Comprising A Non-Naturally Encoded Amino Acid In The A Chain In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 10,751,391 | Methods of Treatment Using Modified Relaxin Polypeptides Comprising a Non-Naturally Encoded Amino Acid In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 11,786,578 | Modified Relaxin Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 9,567,386 | Therapeutic Uses of Modified Relaxin Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 11,311,605 | Methods of Treating Heart Failure and Fibrotic Disorders Using Modified Relaxin Polypeptides Lapsed Apr 26, 2026 on the fee record Ended Apr 26, 2026 · High confidence | Ambrx, Inc. | Lapsed Apr 26, 2026 on the fee record | Ended Apr 26, 2026 | High confidence | |
| US 9,962,450 | Method of Treating Heart Failure with Modified Relaxin Polypeptides Lapsed May 8, 2026 on the fee record Ended May 8, 2026 · High confidence | Ambrx, Inc. | Lapsed May 8, 2026 on the fee record | Ended May 8, 2026 | High confidence | |
| US 8,735,539 | Relaxin Polypeptides Comprising Non-Naturally Encoded Amino Acids Lapsed May 27, 2026 on the fee record Ended May 27, 2026 · High confidence | Ambrx, Inc. | Lapsed May 27, 2026 on the fee record | Ended May 27, 2026 | High confidence | |
| US 11,439,710 | Nucleic Acids Encoding Modified Relaxin Polypeptides Lapsed Sep 13, 2026 on the fee record Ended Sep 13, 2026 · High confidence | Ambrx, Inc. | Lapsed Sep 13, 2026 on the fee record | Ended Sep 13, 2026 | High confidence | |
| 2 more patents in this group · Pro | ||||||
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12, including 4 expired.
6 of these are in force and held by Ambrx, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.